1Mohr JP. Thomas Willis Lecture. Acute clinical trials: An expression of concern. Cerebrovasc Dis, 1999, 9 ( Suppl 3 ): 45-50.
2Dyker AG, Lees KR. Duration of neuroprotective treatment for ischemic stroke. Stroke, 1998, 29(2): 535-442.
3De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: are we doing the right thing? Trends Neurosci, 1999, 22(12): 535-540.
4Orgogozo JM. Advantages and disadvantages of neurological scales.Cerebrovasc Dis, 1998, 8 ( Suppl2 ): 2-7.
8Latha G. Stead,Rachel M. Gilmore,M. Fernanda Bellolio,Shaily Mishra,Anjali Bhagra,Lekshmi Vaidyanathan,Wyatt W. Decker,Robert D. Brown.Hyperglycemia as An Independent Predictor of Worse Outcome in Non-diabetic Patients Presenting with Acute Ischemic Stroke[J].Neurocritical Care.2009(2)
9Capes SE,Hunt D,Malmberg K,el al.Strees hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients:A systematic overview[].Stroke.2001
10Bravata DM,Kim N,Concato J,et a1.Hyperglycaemia in patients with acute ischaemic stroke:how ofter do we screen for undiagnosed diabetes[].Quarterly Journal of Mathematics.2003
